AOD-9604 research: studies, doses and safety

A growth-hormone fragment whose largest obesity trial failed to show meaningful weight loss.

Also called: AOD9604, Tyr-hGH177-191, LAT8881, LAT-8881, HGH fragment 176-191.

Fat-loss peptides · Modified C-terminal growth-hormone fragment.

Nine intervention studies found: six original trials and three LAT8881 trials. The largest obesity trial failed; subcutaneous efficacy remains untested.

Key studies

  • First IV safety study: A small IV safety study; it did not test routine fat-loss injections. (source)
  • IV doses in obesity: IV exposure produced some possible drug-related symptoms; fat-loss efficacy was not established. (source)
  • Single oral doses: Single oral doses were tested; this is not evidence for under-the-skin dosing. (source)
  • Seven days of oral dosing: 54 mg daily caused more symptoms than lower doses over one week. (source)
  • 12-week obesity dose finding: A small, irregular weight-loss signal was reported; the larger follow-up trial failed. (source)
  • OPTIONS: failed obesity trial: The largest obesity trial failed; Metabolic stopped obesity development in February 2007. (source)

Related to AOD-9604

Sources

Sources checked: 2026-10-18.

Information only, not medical advice. Peptifacts does not sell anything and does not link to sellers.